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ABSTRACT
Oral consumption of probiotics is practical and can be an effective solution to preserve vaginal eubiosis. Here, we studied
the ability of orally administered Lactobacillus paracasei LPC-S01 (DSM 26760) to affect the composition of the vaginal
microbiota and colonize the vaginal mucosa in nondiseased adult women. A total of 40 volunteers took oral probiotic (24
billion CFU) or placebo capsules daily for 4 weeks, and after a 4-week washout, they switched to placebo or probiotic
capsules according to the crossover design. A total of 23 volunteers completed the study according to the protocol. Before
and after capsule ingestion, vaginal swabs were collected for qPCR quantification to detect L. paracasei LPC-S01 and for 16S
rRNA gene sequencing. Vaginal swabs were grouped according to their bacterial taxonomic structure into nine community
state types (CSTs), four of which were dominated by lactobacilli. Lactobacillus paracasei LPC-S01 was detected in the vagina
of two participants. Statistical modeling (including linear mixed-effects model analysis) demonstrated that daily intake of
probiotic capsules reduced the relative abundance of Gardnerella spp. Quantitative PCR with Gardnerella vaginalis primers
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confirmed this result. Considering the pathogenic nature of G. vaginalis, these results suggest a potential positive effect of
this probiotic capsule on the vaginal microbial ecosystem.
Keywords: probiotic; Lactobacillus; vaginal microbiota; community state types; Gardnerella; 16S rRNA gene profiling
INTRODUCTION
The human vagina represents a unique microbial ecosystem.
Compared to that of other body sites, the vaginal microbiota
is characterized by very low α-diversity (particularly in terms
of evenness) and high intersubject variability (Zhou et al. 2013).
In addition, the human vaginal environment is unique com-
pared to that of other mammals, since it has a pH lower than
5 as a consequence of the abundant presence of a single acid-
producing taxonomic bacterial group, i.e. lactobacilli (Miller et al.
2016). In particular, the vaginal microbiota of healthy women
colonizes the approximately 1–4 ml of glycogen-rich fluid pro-
duced by the mucosa at a concentration of approximately 106–
108 cells/ml (Danielsson, Teigen and Moi 2011). Specifically, the
vaginal microbial ecosystem is nearly completely constituted
by bacteria, 70% of which are most commonly represented by
the homofermentative Lactobacillus species Lactobacillus crispa-
tus, Lactobacillus iners, Lactobacillus gasseri and/or Lactobacillus
jensenii (Ravel et al. 2011).
The vaginal mucosa and its microbial commensals interact
closely, influencing different aspects of women’s health, pri-
marily fertility and susceptibility to infections (Smith and Ravel
2017). Specifically, autochthonous lactobacilli are believed to
preserve vaginal health through various mechanisms, includ-
ing the direct inhibition of pathogens associated with vaginosis
(e.g. Candida albicans, Gardnerella vaginalis, Escherichia coli, Lep-
totrichia spp., Mobiluncus spp., Mycoplasma spp., Peptostreptococ-
cus spp., Peptoniphilus spp., Prevotella spp., Sneathia spp., Staphy-
lococcus aureus and Streptococcus agalactiae) through competitive
exclusion for adhesion sites and nutrients, lactic acid produc-
tion and bacteriocin secretion; the promotion of vaginal epithe-
lial integrity (stimulating the secretion of mucin) and the mod-
ulation of immune responses (Younes et al. 2018).
The most common alterations in the composition of
the vaginal microbiota involve a decrease in the presence
of lactobacilli, excessive growth of a mixed microbial flora
and increased microbial biodiversity (Onderdonk, Delaney
and Fichorova 2016). This polymicrobial condition of vaginal
mucosal dysbiosis, which is often associated with an abnormal
odorous vaginal discharge, is associated with vulvovaginal con-
ditions such as bacterial vaginosis (BV, also known as vaginal
bacteriosis) and aerobic vaginitis. BV, although it may not be
considered a disease in itself (Reid 2018), seems to promote
pathological and infectious conditions. In fact, BV has been
associated with an increased risk of contraction of sexually
transmitted diseases, preterm birth and maternal or neonatal
infections (van de Wijgert and Jespers 2017).
The maintenance of microbial homeostasis in the human
vagina is therefore a fundamental condition for female health.
In this context, the administration of probiotics, i.e. livemicroor-
ganisms that can benefit health when administered in an ade-
quate amount (Hill et al. 2014), is a practical and potentially effec-
tive strategy for preserving the eubiosis of the vaginal microbial
ecosystem. Probiotics have been reported to be effective in the
prevention and treatment of BV (Huang, Song and Zhao 2014)
and urinary tract infections (Grin et al. 2013). Various probiotic
products for benefiting vaginal health are available on the mar-
ket and predominantly contain lactobacilli; some of these Lacto-
bacillus strains have been isolated from the vaginal mucosa (e.g.
L. reuteri RC-14); (Reid, Cook and Bruce 1987; Zhong et al. 1998) or
from the urethra (e.g. L. rhamnosus GR-1); (Petrova et al. 2018) of
healthywomen and are administered in formulations for topical
application in the form of tablets, ovules, capsules, gel or laven-
ders. Intriguingly, it has been suggested that oral administra-
tion may also have a positive influence on the vaginal microbial
ecosystem (Macklaim et al. 2015). The idea of administering oral
probiotic lactobacilli to benefit vaginal health originates from
the hypothesis that these bacteria, which are adapted to colo-
nize the mucous membrane of the vagina, can migrate from the
gut and benefit vaginal health, similarly to several pathogens,
which can ascend from the rectum and perineal skin to cause
urogenital tract infections (Ahrne´, Jeppsson andMolin 2005; Reid
2017). This hypothesis is supported by several studies report-
ing that orally administered lactobacilli can (i) migrate to the
vagina (Reid et al. 2001a; Reid et al. 2001b; Reid et al. 2003; Morelli
et al. 2004), (ii) reduce vaginal and rectal colonization by uro-
genital pathogens (Ho et al. 2016) and (iii) improve immune
responses systemically through local (intestinal) immunomod-
ulation (Lorea Baroja et al. 2007).
In the context described above, we show the results of an
intervention study carried out by administering a vaginal Lac-
tobacillus isolate per os to healthy women of reproductive age.
We used a bacterial strain originally isolated from the vaginal
mucosa of a healthy adult woman (Lactobacillus paracasei LPC-
S01). This strain has been shown to possess characteristics com-
patible with its use as an intestinal probiotic, such as the abil-
ity to resist gastrointestinal transit in vivo, adhere to the intesti-
nal epithelium in vitro and reduce NF-κB activation in the pres-
ence of inflammatory stimulation in polarized Caco-2 intesti-
nal epithelial cells (Balzaretti et al. 2015). Such potential pro-
biotic features of strain LPC-S01 may contribute to preventing
intestinal dysfunctions, which have been associated with vagi-
nal health (Reed et al. 2012; Drummond et al. 2016). The primary
endpoint of this study was to assess the impact of LPC-S01 on
the vaginal microbiota composition; in addition, we evaluated
the ability of this strain to migrate to the vaginal mucosa once
ingested.
MATERIALS AND METHODS
Intervention trial
The VAG-LPC14 study was a randomized, double blind, placebo-
controlled crossover trial (Fig. 1). The primary endpoint of the
study was the evaluation of the ability of the probiotic strain to
reach the vaginal environment and modify the composition of
the vaginal microbiota. The study protocol was approved by the
Research Ethics Committee of the Sacco Hospital, University of
Milan (opinion no. 00 19288, 24/07/2015). A total of 40 healthy
women of reproductive age (18 to 45 years) fulfilling all inclu-
sion and exclusion criteria were randomized and entered the
run-in phase according to the scheme shown in Fig. 1 (group
A: probiotic first, n = 19, age ± standard deviation 30.4 ± 6.7
years; group B: placebo first, n=18, 30.5 ± 6.2 years). Each vol-
unteer orally took one probiotic (24 billion CFU) or placebo cap-
sule at least 10 min before breakfast every day for 4 weeks, and
after a 4-week washout, they switched to placebo or probiotic
capsules according to the crossover design. A 4-week interval
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Figure 1. Diagram of study design and flow.
between treatments was adopted, as it was shown to be suf-
ficient for complete washout of probiotic cells from the gut in
previous intervention trials carried out with an identical design
(Ferrario et al. 2014; Gargari et al. 2016). Detailed information on
the study participants and experimental protocol are provided
in the Supplementary Methods.
Probiotic and placebo capsules
The probiotic preparation (Pregyn R©, Sofar S.p.A.) consisted of a
gelatin capsule containing at least 24 billion viable cells of the
bacterial strain L. paracasei LPC-S01 (deposited in the Deutsche
Sammlung von Mikroorganismen und Zellkulturen (DSMZ) cul-
ture collection under the code DSM 2760; LPC-S01). The cap-
sules contained silicon dioxide andmagnesium stearate as anti-
agglomerants and were externally colored with titanium diox-
ide. The placebo and probiotic capsules were identical in color
and shape. The placebo and probiotic capsules were directly
provided in metal boxes with a plastic cap containing desic-
cant salts by the manufacturer of the Pregyn R© probiotic product
(Sofar S.p.A.).
Vaginal sample collection and total DNA extraction
Vaginal swabs were collected by the gynecologist (in the Depart-
ment of Biomedical and Clinical Sciences, Unit of Obstetrics
and Gynecology, ASST Fatebenefratelli Sacco University Hospi-
tal, University of Milan, Milan, Italy) following the standard vagi-
nal swab collection procedure mentioned in the Manual of Pro-
cedures for Human Microbiome Project at visits V1, V2, V3 and
V4 (according to the scheme in Fig. 1), transferred into 750 μl of
PowerBead solution (QiagenGmbH,Hilden, Germany) and stored
at -80◦C until they were processed for DNA extraction. In addi-
tion, during visits V1 to V4, the volunteers delivered a fecal sam-
ple collected during the previous 24 h in a special container that
was provided during visit V0. The fecal specimens were also
stored at -80◦C until they were processed for DNA extraction, as
follows. Vaginal swabs in PowerBead Solution were thawed on
ice. Swabs were pressed several times by rotating on the inner
wall of the sampling tube to release the entire amount of buffer
or vaginal mucus adhered on the swab under aseptic conditions
(later swabswere used for isolation of the target probiotic strain).
Samples were then processed using a DNeasy R© PowerLyzer R©
PowerSoil R© Kit (Qiagen GmbH) with a minor modification con-
sisting of sample incubation in PowerBead solution at 65◦C for
10min after the addition of C1 solution. Mechanical lysis of cells
was carried out using a bead beater (Precellys 24, Bertin Tech-
nologies, Montigny le Bretonneux, France). A similar procedure
was followed for DNA extraction from fecal samples. Specifi-
cally, after thawing on ice, samples were mixed vigorously for
2–3 min with a sterile spatula. Samples were weighed (250 mg)
in a PowerBead tube, and DNA extraction was carried out as
mentioned above. The DNA obtained from either vaginal or fecal
samples was quantified in Take3 Micro-Volume plates analyzed
in a microplate reader with Gen5 software (BioTek Instruments,
Inc., Winooski, VT, USA), diluted to 10 ng/μl and stored at -80◦C
until use.
Quantification of L. paracasei LPC-S01 in vaginal and fecal
samples through quantitative PCR
The probiotic strain L. paracasei LPC-S01 was quanti-
fied in both vaginal and fecal samples by means of
quantitative PCR (qPCR) with the strain-specific primers
qS01a-F (5′-TGGAAGAGACCCTGCGAA-3′) and qS01a-R (5′-
GAGGTTGATTCACAAACCGTGC-3′). These primers targeted a
hypothetical protein coding sequence in the draft genome of
strain LPC-S01 (Balzaretti et al. 2015) with an expected amplicon
size of 181 bp. In addition, the total number of bacteria was
quantified using the panbacterial primers 357F-907R, which
targeted the V3-V5 region of the 16S rRNA gene (Muyzer, de
Waal and Uitterlinden 1993). qPCR amplification was carried
out in a final volume of 15 μl containing 7.5 μl of EvaGreen R©
Supermix (Bio-Rad Laboratories S.r.l., Segrate, Italy), 0.5 μM
each primer and 50 ng of metagenomic DNA from vaginal or
fecal samples. Amplification was carried out using the following
thermal cycling conditions: an initial hold at 95◦C for 3 min and
39 cycles at 95◦C for 30 s, 58◦C for 30 s and 72◦C for 30 s. Melting
curves were analyzed with Bio-Rad CFX Manager 3.1 to confirm
the specificity of the amplification products. A standard calibra-
tion curve for quantification of LPC-S01 cells was prepared by
mixing different numbers of LPC-S01 cells from vaginal swabs.
For this purpose, several vaginal swab samples were collected
from the volunteers and transferred into 750 μl of PowerBead
solution. The swab samples were combined in one tube, mixed
vigorously and equally distributed into seven tubes. After
quantification of L. paracasei LPC-S01 in a C6 Plus BD AccuriTM
flow cytometer (BD Biosciences, San Jose, CA, USA), probiotic
cells were added to each swab sample (from 106 to 101 cells),
except for one sample used as a control without the addition
of bacterial cells; then, DNA was extracted as described above.
Similarly, a standard calibration curve for quantification of the
probiotic strain in fecal samples was prepared as previously
described (Arioli et al. 2018). In addition, the standard calibra-
tion curve for quantification of the total bacterial cell count in
vaginal swab samples was prepared by creating a vaginal swab
pool. For this purpose, vaginal swab samples were provided by
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volunteers in 750 μl of PowerBead solution and pooled. Then,
the vaginal swab pool was mixed properly and concentrated by
centrifugation. After determination of the total bacterial cell
concentration by flow cytometry, the concentrated swab pool
was serially diluted, and each dilution was subjected to DNA
extraction following the abovementioned procedures. Then,
DNA obtained from these different dilutions of the vaginal
swab pool was used for quantitative PCR to generate a standard
calibration curve for estimation of the total bacterial cell count
in vaginal swab samples collected in the study.
Quantification of G. vaginalis in vaginal samples through
qPCR
The abundance of G. vaginalis in vaginal swab samples
was quantified by qPCR with the species-specific primers
Gard LdhF, 5′-GTTATTACTGCTGGTGCTCG-3′ and Gard LdhR, 5′-
GCTCGCCAGCAATATAAGCG-3′, which targeted the lactate dehy-
drogenase gene, with an expected amplicon size of 301 bp
according to the protocol provided in the supplementary mate-
rial.
Isolation of L. paracasei LPC-S01 from vaginal swabs
After aseptic processing for total DNA extraction, vaginal swabs
were transferred into de Man-Rogosa-Sharpe (MRS) broth (pH
6.5) supplemented with ribose (1% w/v), vancomycin (1 μg/ml)
and kanamycin (10 μg/ml) (rvkMRS) for semiselective isolation
of the probiotic strain. The swab-inoculated broth tubes were
incubated at 37◦C for 48 h under anaerobic conditions (Anae-
rocult A, Merck KGaA, Darmstadt, Germany). The broth cultures
were used for DNA extraction and qPCR with LPC-S01-specific
primers as described above. Simultaneously, each culture broth
was spread on agar medium (rvkMRS agar). Randomly selected
colonies were examined under a microscope to determine their
morphology andwere identified by colony PCR (Arioli et al. 2018).
16S rRNA gene profiling of vaginal samples
To establish whether oral administration of the vaginal bac-
terium L. paracasei LPC-S01 modified the composition of the
vaginal microbiota, we used 16S rRNA gene profiling to ana-
lyze four vaginal swabs per subject collected from women who
completed the intervention study according to the protocol (n
= 24). Specifically, the vaginal bacterial community was charac-
terized immediately before and after the probiotic and placebo
phases, according to the crossover scheme shown in Fig. 1. DNA
extracted from vaginal swabs was analyzed at the Institute for
Genome Sciences (University of Maryland, School of Medicine,
Baltimore, MD, USA) through 16S rRNA gene profiling with
Illumina HiSeq 2500 rapid run sequencing of the V3-V4 vari-
able region (forward primer, 5′-ACTCCTRCGGGAGGCAGCAG-3′;
reverse primer, 5′-GGACTACHVHHHTWTCTAAT-3′), which was
performed using a two step-PCR protocol as described in detail
in (Elovitz et al. 2019). The 16S rRNA gene profiling data for the
analysis of vaginal microbiota were analyzed using R statistical
software (version 3.1.2) with the DADA2 software package (Calla-
han et al. 2016) associated with the taxonomic assignment tool
speciateIT. For the V3-V4 region, DADA2 used reads truncated
after nt 255 for forward reads and at nt 225 for reverse reads.
Taxonomic assignment was performed with the SILVA database
according to a custom pipeline freely available on GitHub (https:
//github.com/Ravel-Laboratory/speciateIT). α-Diversity (Chao1,
Simpson, invSimpson and Shannon) and β-diversity index anal-
yses were performed using R software to describe the intra- and
intersubject diversity, respectively. Stratification of the vaginal
microbiota into community state types (CSTs) was carried out
on the basis of the relative abundance of the most represented
taxon in the sample, using 50% of total reads per sample as
the cutoff. If no taxon in a sample exceeded an abundance of
50%, that sample was assigned to CST IV. Metadata have been
deposited in the European Nucleotide Archive of the European
Bioinformatics Institute under accession code PRJEB30833.
Statistical analysis
Statistically significant changes in the relative abundances of
bacterial taxa were determined through the Wilcoxon signed
rank test for paired data using the Benjamini-Hochberg correc-
tion (Haynes 2013) when needed. Correlation analyses with the
relative abundances of vaginal taxa were performed using the
Kendall and Spearman formulas. Significancewas set at P≤ 0.05;
significance in the range of 0.05 < P < 0.10 was accepted as a
trend. To find associations among the probiotic treatment and
changes in bacterial relative abundances, a machine learning
supervised linear mixed model (LMM) algorithm was adopted
using the ‘lmer’ function in the ‘lme4’ library (Bates et al. 2015)
in R statistical software (version 3.4.2). LMM fit was tested with
the Akaike information criterion. The nonparametric analysis of
similarities statistical test (ANOSIM) was used to infer significant
differences among CST groups.
RESULTS
Baseline composition of the vaginal microbiota of the
volunteers
We analyzed the vaginal microbiota of the 37 healthy (nondis-
eased) volunteers who entered the run-in phase (Fig. 1). For this
purpose, 16S rRNA gene profiling was performed on a vaginal
swab collected from each subject at the beginning of the inter-
vention (baseline; time point V1 in Fig. 1). The number of total
reads generated was 6,470,846 for the 109 total vaginal samples,
with an average of 30 097 reads per sample. The number of fil-
tered total reads was 5,501,139, and of these, 5,099,077 reads
had been merged. In particular, the number of merged reads
per vaginal sample was 13,340± 8,677 (mean ± standard devi-
ation) (range, 4,570–11,594). Following taxonomic assignment of
the sequencing reads, we found a total of 69 bacterial taxa (mean
of 17 and median of 15 taxa per sample). No taxon was found in
all subjects. The most dominant bacteria were L. crispatus and
L. iners, each detected in 68% of subjects, followed by members
of the genera Finegoldia (65%), Streptococcus (65%) and Bifidobac-
terium (62%). All other taxa were found in less than 50% of the
subjects. In particular, further taxonomic analysis of the reads
assigned to Bifidobacterium carried out by manual screening of
GenBank (database of 16S ribosomal RNA sequences) through
BLASTn suggested that most of these reads corresponded to the
species B. breve (79% of the Bifidobacterium spp. reads) and B.
longum (21%) (not shown).
Analysis of the vaginal microbiota taxonomic composition
at baseline (V1) allowed stratification of samples into eight dis-
tinct types of bacterial communities, named CSTs, that differed
in both the composition and relative abundance of taxa (Ravel
et al. 2011) (CSTs; Fig. S1, Supporting Information). Five of these
CSTs (from I toV) resembled theCSTs originally described for the
human vaginal microbial ecosystem (Ravel et al. 2011). In addi-
tion, we found three more CSTs dominated by members of the
genera Bifidobacterium, Streptococcus and Alloscardovia. The most
prevalent CSTs were I (L. crispatus-dominant; found in 32% of
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subjects; n = 12), III (L. iners-dominant; 24%; n = 9) and IV (mixed
community; 14%; n = 5). In contrast to the other CSTs, CST IV
was characterized by the absence of a dominant taxon (i.e. one
accounting for more than 50% of the reads), as also evidenced
by the inverse Simpson α-diversity index, used as a measure of
taxonomic evenness (Fig. S1, Supporting Information).
Principal component analysis (PCA) was performed using the
relative abundances of bacterial taxa in each subject at baseline
(V1) to visualize the relationships among vaginal bacterial com-
munities (Fig. 2A). In the resulting two-dimensional PCA load-
ing plot, which explained 70% of the diversity, the L. crispatus-
dominant (I) and L. iners-dominant (III) CSTs clustered separately
from the other samples (ANOSIM r = 0.98, P < 0.01; Fig. 2A).
Impact of oral administration of L. paracasei LPC-S01 on
the vaginal microbiota composition
We also used PCA as described above to visualize the vaginal
bacterial communities of all vaginal swab samples collected dur-
ing the study (Fig. 2B). This analysis confirmed the distribution
observed using the baseline samples, with bacterial communi-
ties assigned to CSTs I and III that clustered separately from
the others (ANOSIM r = 0.97, P < 0.01; Fig. 2B). In general, the
CSTs were mostly stable; in fact, of 72 possible transitions (24
subjects per 3 phases, i.e. probiotic, washout, and placebo), the
CST changed 16 times (21%): 7 times during the placebo phase,
5 times during the washout and 4 times during the probiotic
administration phase (Fig. 3). In particular, CST-I was the most
stable: of 30 possible transitions (n = 10), this CST changed only
twice (Fig. 3).
Subsequently, to identify whether probiotic intake modified
the relative abundance of specific taxa, we performed statisti-
cal analysis with the Wilcoxon signed rank test for taxa that
were present in at least 30% of the samples (arbitrary limit). We
did not find any significant modification of bacterial taxa upon
intervention with placebo; in contrast, after probiotic intake,
we found a significant decrease in the genus Gardnerella (P =
0.049; Fig. 4) and an increasing trend for the species L. gasseri
(P = 0.078; Fig. 4). Subsequently, bacterial relative abundance
data were also analyzed by means of LMM analysis to observe
the predictive power for the changes in the bacterial community
due to the treatment. LMM analysis revealed a significant asso-
ciation with treatment only for the genus Sutterella (P = 0.035)
and a trend toward significance for Gardnerella (P = 0.080) and
L. crispatus (P = 0.085). A significant reduction in the abundance
of Gardnerella over the course of probiotic intervention was also
observed by qPCR, which was performed using G. vaginalis-
specific primers on DNA extracted from vaginal swabs (Fig. S2,
Supporting Information).
Tolerability and safety of the intervention
Two subjects, viz., S17 and S18, experienced at least one adverse
event while being treated with the placebo or Pregyn R©, respec-
tively. No serious adverse events occurred. Table S1 (Supporting
Information) summarizes the adverse events that occurred dur-
ing the trial. Most of the events suspected to be related to the
treatment were gastrointestinal disorders (abdominal pain, con-
stipation, diarrhea, dyspepsia, flatulence, meteorism and nau-
sea), and no significant difference between treatment groups
was detected. The total number of adverse events and the num-
ber of events per subject did not differ between the two treat-
ments, nor did the number of adverse events suspected to be
related to the treatment.
Effect of probiotic treatment on the predicted metabolic
potential of the vaginal microbiota
The 16S rRNA amplicon sequencing data set was also used to
infer the functional contribution of the vaginal bacterial com-
munities by means of the PICRUSt computational approach.
Analysis of the obtained functional gene count matrix revealed
that the relative levels of 34 putative genes changed during the
placebo phase (32 genes increased and 2 decreased), whereas
only 10 potential bacterial genes were significantly modified
(9 increased and 1 decreased) during the probiotic phase. The
results of a BLASTP search (not shown) showed that most of the
predicted genes that increased in the placebo phase (n = 21) but
did not change during the probiotic intervention phase, were not
present in the genome of homofermentative lactobacilli (e.g. L.
crispatus, L. iners, L. gasseri and L. jensenii). These genes included
eight predicted genes involved in the tricarboxylic acid cycle and
the genes encoding indolepyruvate ferredoxin oxidoreductase,
the type IV pilus assembly protein PilC and glutathionylspermi-
dine synthase (Fig. S3, Supporting Information). In addition, the
only predicted genes with reduced levels in the placebo phase
are putatively involved in the synthesis of nicotinate and nicoti-
namide. In contrast, half of the predicted genes with increased
levels during the probiotic phase (n= 5) putatively encodemem-
brane transport proteins.
Recovery of strain L. paracasei LPC-S01 from the vaginas
of volunteers
16S rRNA gene profiling of vaginal swabs revealed the pres-
ence of reads taxonomically assigned to L. paracasei/L. rhamno-
sus group in 3 subjects (S1, S17, and S32; Fig. 5A). In particular, L.
paracasei/L. rhamnosus reads appeared in these three volunteers
after probiotic intervention (Fig. 5A); therefore, we hypothesized
that these results might have been a consequence of the migra-
tion of L. paracasei LPC-S01 from the gut to the vaginal mucosa.
To test this hypothesis, we performed qPCR analyses with LPC-
S01-specific primers using DNA isolated from all vaginal swabs
collected during the study. According to 16S rRNA gene profil-
ing, significant amplification was obtained only for subjects S1
(for the swab collected at V2) and S17 (at V2 and V3), not for S32
(Fig. 5B). In addition, we were able to isolate LPC-S01 on rvkMRS
agar plates only from the swabs collected from subject S17 at V2,
V3 and V4 (Fig. 5B).
Strain-specific qPCR experiments were also carried out to
quantify L. paracasei LPC-S01 in fecal samples. LPC-S01 was
detected exclusively in fecal samples collected at the end of the
probiotic intake period for 21 of 23 investigated volunteers at
concentrations ranging between 5.6 and 8.1 log10 cells per gram
of feces (Fig. S4).
Correlations among vaginal bacterial taxa
Finally, we performed correlation analyses to assess the poten-
tial associations among the different bacterial taxa within the
vaginal microbiota. To this end, Spearman and Kendall tests
were performed considering the four sets of data obtained over
the course of the intervention (i.e. before and after the probiotic
and before and after the placebo intake phases) and with the
median data from four samples per subject. Each profiling data
set obtained provides information at a single time point for each
volunteer and may have limitations connected to the variabil-
ity of the microbiota over time; on the other hand, the analysis
of median profiling data may include error that depends on the
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Figure 2. PCA plots obtained using the relative abundances of bacterial taxa in each vaginal swab. Each point in the plots indicates a single vaginal swab. The color of
each dot in the plots indicates the CST of the sample according to the legend reported under the chart; the colors correspond to the colors used in Fig. 3. A, baseline
samples (n = 37, i.e. vaginal samples collected at V1 from the 24 volunteers who completed the study and 13 who dropped out); B, all samples (n = 109, i.e. the 37
samples collected at V1 and the samples collected at V2, V3 and V4 from the 24 volunteers who completed the study).
Figure 3. Composition of the vaginal microbiota of the 24 reproductive-age women who completed the VAG-LPC14 study (see Fig. 1 for details on the study design).
The green-white-red heatmap indicates the ages of volunteers; the age in years is indicated in each box. The black-yellow heatmap represents the α-diversity indices,
where the color indicates the values from minimum (black) to maximum for each respective index. The green-yellow-red heatmap represents the log10-transformed
relative abundances ofmicrobial taxa found in the vaginal bacterial communities. a, CST observed for vaginal samples at each visit; each color corresponds to a specific
CST according to the legend reported on the right. Subjects are clustered according to the CST observed at visit 1.
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Figure 4. Relative abundance of vaginal bacterial taxa that were significantlymodified during the interventions (n= 24). Volunteers who tested positive for the presence
of the probiotic strain LPC-S01 in a vaginal swab are represented in red (S01) and violet (S17). The subject code is indicated for higher-abundance samples. Statistically
significant differences were determined according to the Wilcoxon signed rank test. The dotted lines indicate the subjects randomly selected to receive the probiotic
first.
Figure 5. Recovery of L. paracasei LPC-S01 in vaginal swabs. A, histograms indicating the bacterial composition of vaginal swabs as determined by 16S rRNA gene
profiling; only volunteers who tested positive for the presence of sequencing reads assigned to the taxonomic group L. paracasei/L. rhamnosus are shown. B, qPCR
quantification of L. paracasei LPC-S01 (with strain-specific primers) and total bacteria (with pan-bacterial primers) in fecal and vaginal samples. Samples from which
LPC-S01 were isolated on agar plates are shown in the black circle. Only those subjects whose vaginal swabs were positive for LPC-S01 are shown.
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influence of the probiotic intervention. Therefore, we combined
the results of the different analyses to compensate for limita-
tions and identify more plausibly valid (stable) correlations.
These analyses showed that significant correlations among
vaginal microbial taxa decreased from 47 to 22 and from 43 to
29 during the probiotic and placebo interventions, respectively,
whereas the median profiling data revealed 38 significant corre-
lations (Fig. 6). Thirteen correlations were found in all five analy-
ses (Fig. 6). Specifically, we consistently found a significant posi-
tive association among the five vaginal commensal genera Dial-
ister, Anaerococcus, Peptoniphilus, Finegoldia and Prevotella; in addi-
tion, we observed a positive association between theActinobacte-
ria genera Bifidobacterium andAtopobium. In all analyses, L. crispa-
tuswas negatively associatedwith L. gasseri, whereas L. inerswas
positively correlated with the genus Gardnerella.
Overall, these results suggest that the presence and abun-
dance of specific vaginal bacterial taxa are mutually associated.
DISCUSSION
To establish the effect of the administration of the L. paracasei
LPC-S01 strain on the composition of the vaginal microbiota, a
crossover study design was adopted. This choice was made to
address the high intersubject diversity that reportedly charac-
terizes themicrobial ecosystem of the human vagina (Zhou et al.
2013). Characterization of the volunteers at baseline confirmed
the expected high β-diversity of the vaginal microbiota, high-
lighting a clear stratification in CSTs for this microbial ecosys-
tem (Fig. 2; Ravel et al. 2011). Of the eight CSTs identified in this
study, five corresponded to those originally described by Ravel
et al. 2011. In addition, subjects whose vaginalmucosawas dom-
inated by other bacterial genera, i.e. Alloscardovia, Streptococcus
and Bifidobacterium, were identified. The first two genera could
characterize transitional states, as suggested by the fact that
these community states were not identified in any other anal-
yses of these or other volunteers. In contrast, the CST domi-
nated by the genus Bifidobacterium, which was identified in four
subjects at baseline, was shown to be constant throughout the
study for the only subject among these four (S24) who com-
pleted the trial according to the protocol (Fig. S1 (Supporting
Information) and Fig. 3). The presence of Bifidobacterium spp. as
dominant members of the vaginal microbiota of some healthy
reproductive-age women has already been reported (Hyman
et al. 2005; Albert et al. 2015). In particular, Freitas and Hill (Fre-
itas and Hill 2017) showed that bifidobacterial strains isolated
from healthy vaginal mucosae produce lactic acid at levels com-
parable to those produced by L. crispatus (the species most com-
monly associated with a healthy vaginal microbial ecosystem)
and may tolerate the low pH of the vaginal environment well.
On this basis, Freitas and Hill proposed that bifidobacteria may
be as protective as lactobacilli. Similarly, Campisciano et al. pro-
posed that bifidobacteria (particularly B. breve) may counteract
the poor colonization of the vaginal mucosa by lactobacilli, pre-
serving vaginal health primarily through the production of lactic
acid (Campisciano et al. 2018). Themost abundant end product of
Bifidobacterium catabolism is acetic acid (theoretically, 1.5 moles
of acetate and 1mole of lactate are produced from 1mole of glu-
cose), which may lower the pH as efficiently as lactic acid and is
known to possess antimicrobial activity. It can therefore be spec-
ulated that, in addition to lactic acid, acetic acid produced in situ
by bifidobacteria may contribute to the maintenance of vaginal
health.
The impact of probiotics on the vaginal microbiota has often
been investigated under physiological conditions characterized
by an altered vaginal microbial ecosystem, such as BV (Bodean
et al. 2013), aerobic vaginitis (Heczko et al. 2015) and other vaginal
infections (Vujic et al. 2013), or after antibiotic therapy (Martinez
et al. 2009). Among probiotic products, those intended for intrav-
aginal administration have been most commonly investigated
(Bisanz et al. 2014; Kovachev and Vatcheva-Dobrevska 2015; Ver-
denelli et al. 2016). In contrast, intervention studieswith oral pro-
biotics involving healthy (nondiseased) populations are limited.
For instance, administration of a multispecies probiotic product
for 4weekswas shown to limit the decrease in bifidobacteria and
the increase in Atopobium spp. occurring in the vagina of women
during late pregnancy, as determined through qPCR analysis
(Vitali et al. 2012). On the other hand, Gille et al. reported that the
effect of an 8-week oral administration of the human urogenital
strains L. rhamnosusGR-1 and L. reuteriRC-14 (109 colony-forming
units) to women with < 12 completed weeks of pregnancy did
not differ from that of placebo on modifying the vaginal micro-
biota composition, as assessed through microscopic observa-
tion (Nugent scoring) (Gille et al. 2016). However, in two other
placebo-controlled trials, Nugent scoring and cultivation exper-
iments revealed that oral administration of the same strains sig-
nificantly increased the level of vaginal lactobacilli (Reid et al.
2001a; Reid et al. 2003), suggesting 108 viable bacterial cells per
day as the required minimal dose (Reid et al. 2001a). An increase
in vaginal Lactobacillus spp. was also reported upon oral intake
of the commercial probiotic strains L. acidophilus La-14 and L.
rhamnosus HN001 in combination with bovine lactoferrin, as
assessed through qPCR (De Alberti et al. 2015). In general, the
assessment of vaginal microbiota modifications induced by pro-
biotic administration in healthy women is made difficult by the
marked stratification of human vaginal bacterial communities
(Zhou et al. 2013). In our study, the probiotic intervention did not
appear to affect the stability of the vaginal CSTs; however, when
we considered specific bacterial taxa, we observed a significant
reduction in the reads ascribed to the genus Gardnerella. Gard-
nerella is a genus in the family Bifidobacteriaceae that—to date—
includes only the species G. vaginalis (according to NCBI Tax-
onomy, https://www.ncbi.nlm.nih.gov/taxonomy; Taxonomy ID:
2701). This anaerobic bacterium commonly exists as a minor-
ity member of the normal (nondysbiotic) vaginal microbiota of
most women (prevalence of approximately 85%; Janulaitiene
et al. 2017), acting as a pathobiont; in fact, an increase in the rel-
ative abundance of G. vaginalis leads to BV and is consequently
associated with preterm birth and an increased risk of acquir-
ing sexually transmitted infections (Kairys and Garg 2018). BV
is a dismicrobism that is characterized by concomitant expan-
sion of several other vaginal pathobionts, such as Atopobium,
Fusobacterium, Mobiluncus, Peptoniphilus and Prevotella, in addi-
tion to G. vaginalis. However, G. vaginalis plays a dominant role
in the onset of this dysbiotic polymicrobial consortium because
it can efficiently adhere to the vaginal epithelium and compete
with lactobacilli (Machado, Jefferson and Cerca 2013), initiating
the establishment of the multibacterial biofilm community that
characterizes BV (Schwebke, Muzny and Josey 2014; Machado
and Cerca 2015). Therefore, although G. vaginalis includes both
virulent and avirulent strains, the observed reduction in Gard-
nerella abundance in the vaginalmicrobial ecosystem induced by
oral intake of L. paracasei LPC-S01 may plausibly favor the main-
tenance of vaginal eubiosis.
The high intersubject taxonomic variability of the vaginal
microbial environment, together with the relatively low num-
ber of volunteers considered in this study, limited the possi-
bility of finding specific bacterial taxa that were significantly
modified by the probiotic intervention. However, despite their
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Figure 6. Correlations among the relative abundances of vaginal bacterial taxa calculated at each of the four phases of the trial (i.e. before and after the probiotic and
the placebo treatments; n = 24). In addition, correlations with median data at the four time points for each volunteer are shown. The squares with bold black margins
highlight the correlations maintained in all five correlation analyses. Only vaginal taxa found in at least 30% of vaginal samples were considered in the analysis.
This figure only includes taxa whose abundance significantly correlated with at least one vaginal taxon according to Kendall’s tau rank correlation. The colors in the
heatmap represent the R-value obtained by Spearman correlation analysis. The asterisks indicate the Kendall’s tau rank correlation: ∗, P < 0.05; ∗∗, P < 0.01; ∗∗∗, P
< 0.001.
high taxonomic variability, microbial communities reportedly
possess a stable functional structure (Louca et al. 2016; Gib-
bons 2017); therefore, we also studied the metabolic potential
of the vaginal microbiota predicted via the PICRUSt bioinfor-
matic tool. This analysis provided four major results: the pre-
dicted genes whose relative abundance was significantly modi-
fied during the placebo phase (i) were approximately three times
greater in number than themodified genes identified for the pro-
biotic treatment (34 genes vs 10 genes, respectively), (ii) were
mostly increased in relative level after the intervention (only 2
decreased), (iii) putatively belonged to the genomes of aerobic
and/or facultative anaerobic bacteria and (iv) were not present
in the genome of the most common commensal lactobacilli
of the human vaginal mucosa. Considering that the human
vaginal microbiota is characterized by high temporal instabil-
ity (Zhou et al. 2013), possibly deriving, for instance, from men-
struation and sexual activity (Eschenbach et al. 2000; Mitchell
et al. 2012), our results on the metabolic potential suggest that
the probiotic intervention may have limited the transition of
the vaginal microbiota toward a lactobacilli-reduced multimi-
crobial community structure that is potentially linked to dysbi-
otic states and may facilitate the colonization and expansion of
Gardnerella.
Our data confirmed that CSTs dominated by L. crispatus (CST-
I) and L. iners (CST-III) were the most common CSTs among
nondiseased women of reproductive age (Ravel et al. 2011). In
particular, we observed that CST-I, which is generally recognized
as the most protective against the acquisition of sexually trans-
mitted diseases (Lewis, Bernstein and Aral 2017), displayed high
stability throughout the study. In contrast, CST-III, dominated
by L. iners, demonstrated transitions to a mixed CST (CST IV) in
three of the six subjects belonging to this group. Accordingly,
the L. iners-dominated vaginal compositional state was shown
to be more commonly transitional toward dysbiosis than were
the other states. L. iners has been associated with preterm deliv-
ery (Petricevic et al. 2014) and increased susceptibility to Chlamy-
dia trachomatis infection (van Houdt et al. 2018). These observa-
tions make it difficult to establish whether L. iners is a ‘friend
or foe’ in the vaginal mucosa (Petrova et al. 2017). However,
the potential pathobiontic attitude of L. iners may be explained
by some physiological and genetic features of this bacterium,
including the production of less lactic acid than L. crispatus and
only in the ‘levo’ optical form (Witkin et al. 2013). In addition, L.
iners has been shown to significantly induce pattern recognition
receptor signaling, resulting in proinflammatory modulation of
the innate immune response (Doerflinger, Throop and Herbst-
Kralovetz 2014). Moreover, L. iners may secrete a cholesterol-
dependent pore-forming toxin named inerolysin, which shares
similarity with vaginolysin, the main virulence factor of G. vagi-
nalis (Rampersaud et al. 2011). The frequent isolation of L. iners
during the transition between BV and non-BV states (Jakobsson
and Forsum2007) is apparently consistentwith the results of our
correlation analyses, which revealed a significant positive asso-
ciation between L. iners and Gardnerella at all studied time points
(Fig. 6).
Correlation analyses showed that the bacterial genera Fine-
goldia, Peptoniphilus, Anaerococcus, Dialister and Prevotella, which
are generally present at high levels in BV, were mutually associ-
ated throughout the entire study. Peptoniphilus, Anaerococcus and
Finegoldia are Gram-positive anaerobic cocci belonging to the Fir-
micutes class Tissierella; these bacteria are part of the commensal
microbiota of several body sites, where they can become oppor-
tunistic pathogens, as demonstrated by their frequent isolation
from clinical specimens, such as blood, and from abscesses and
skin, joint, bone, respiratory tract and urogenital tract infec-
tions (Murdoch 1998; Shilnikova and Dmitrieva 2015). Dialister
is an anaerobic Firmicutes genus of the class Negativicutes; simi-
lar to the other three genera mentioned above, Dialister includes
opportunistic bacteria with pathogenic potential that have been
isolated from various infections, including periodontitis (Con-
treras et al. 2000), endodontic infections (Rolph et al. 2001),
brain abscesses (Rousee et al. 2002), and bacteremia (Pierre Lep-
argneur, Dubreuil and Joseph 2006). Finally, the Gram-negative
genus Prevotella, belonging to the phylum Bacteroidetes, is known
to disrupt innate immune responses in the vaginal epithelium
(Doerflinger, Throop and Herbst-Kralovetz 2014) and was shown
to be the only discriminative bacterium present under several
conditions, including BV, obesity and papillomavirus infection,
in a Korean twin-family cohort (Sung et al. 2006; Si et al. 2017).
These five genera of opportunistic bacteria, which are more
abundant in CST IV, might plausibly proliferate in the vaginal
mucosa when the presence of lactobacilli, especially L. crispa-
tus, decreases. Accordingly, in our study, L. crispatus was the
only vaginal taxon that showed negative associations with sev-
eral other vaginal taxa, including BV-associated bacteria. These
results reinforce the idea that L. crispatus is the most efficacious
vaginal commensal in maintaining the microbial homeostasis
of the human vagina.
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Orally administered probiotics, similar to intestinal bacteria,
have been hypothesized to migrate to the vagina from the intes-
tine (Reid et al. 2001b). Reisolation of probiotics from the vaginal
mucosa upon oral ingestion was first reported by G. Reid et al. for
the strains L. rhamnosus GR-1 and L. fermentum RC-14 (Reid et al.
2001b). However, very few other studies have investigated the
vaginal recovery of orally administered probiotics (Ahrne´, Jepps-
son and Molin 2005). In our study, the bacterial strain investi-
gated, i.e. the vaginal isolate L. paracasei LPC-S01,was detected in
vaginal swabs after oral administration in at least 2 of 24 subjects
who completed the study according to the protocol. The fre-
quency of vaginal recovery of this probiotic strain was therefore
low; however, these results confirm that colonization of the vagi-
nalmucosa by orally ingested Lactobacillus spp.may be a possible
event. Probiotic migration into the vaginal mucosa might have
been limited by possible variations in the ability of LPC-S01 to
colonize the gastrointestinal tract. In support of this hypothesis,
the highest concentration of LPC-S01 in feces was found for sub-
ject S01, whowas one of the two volunteers positive for LPC-S01.
However, there were too few samples to draw any conclusions.
In conclusion, this study confirms that the vaginal micro-
biota of nondiseasedCaucasianwomenof reproductive age from
North Italy can be stratified into the same community struc-
tures previously described for other populations. In addition,
the L. crispatus-dominated CST was confirmed to be the most
common among white reproductive-age women, followed by
the L. iners-dominated CST. Finally, this study shows that the
vaginal bacterial ecosystem of healthy women is quite stable;
however, oral administration of LPC-S01 may influence the rel-
ative abundance of specific taxa such as G. vaginalis. This find-
ing suggests a potential positive effect of this probiotic capsule
on the vaginal microbial ecosystem. To confirm this preliminary
result, further trials must be carried out, preferentially focusing
on women with an intermediate or polymicrobial (i.e. CST IV)
vaginal microbiota.
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